{"id":"xp13512-gsk1838262","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Dizziness"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Somnolence"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by blocking the activity of voltage-gated sodium channels, which are involved in the transmission of nerve impulses. This can help to reduce the frequency of seizures in patients with epilepsy.","oneSentence":"XP13512 is a voltage-gated sodium channel blocker.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:54:59.046Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Partial-onset seizures"}]},"trialDetails":[{"nctId":"NCT01668667","phase":"PHASE4","title":"Gabapentin Enacarbil (GSK1838262) Adult Restless Leg Syndrome (RLS) Post Marketing Commitment Study","status":"COMPLETED","sponsor":"XenoPort, Inc.","startDate":"2012-06","conditions":"Restless Legs Syndrome","enrollment":501},{"nctId":"NCT01332318","phase":"PHASE2","title":"Simulated Driving Study in Restless Legs Syndrome","status":"COMPLETED","sponsor":"XenoPort, Inc.","startDate":"2007-04","conditions":"Restless Legs Syndrome","enrollment":130},{"nctId":"NCT00617461","phase":"PHASE2","title":"A Clinical Study in Subjects With Neuropathic Pain From PHN Who Have Had an Inadequate Response to Gabapentin Treatment","status":"COMPLETED","sponsor":"XenoPort, Inc.","startDate":"2008-03","conditions":"Neuralgia, Postherpetic","enrollment":96},{"nctId":"NCT00333359","phase":"PHASE3","title":"XP13512 (Gabapentin Enacarbil) Extension Study in Patients With Restless Legs Syndrome.","status":"COMPLETED","sponsor":"XenoPort, Inc.","startDate":"2006-06","conditions":"Restless Legs Syndrome","enrollment":581},{"nctId":"NCT01332305","phase":"PHASE2","title":"Dose-Response and Pharmacokinetics of Gabapentin Enacarbil (GEn [XP13512 / GSK1838262]) in Restless Legs Syndrome","status":"COMPLETED","sponsor":"XenoPort, Inc.","startDate":"2007-01","conditions":"Restless Legs Syndrome","enrollment":217},{"nctId":"NCT00365352","phase":"PHASE3","title":"XP13512 vs. Placebo in Patients With Restless Legs Syndrome.","status":"COMPLETED","sponsor":"XenoPort, Inc.","startDate":"2006-08","conditions":"Restless Legs Syndrome","enrollment":325},{"nctId":"NCT00619476","phase":"PHASE2","title":"A Study In Patients With Neuropathic Pain From Post-Herpetic Neuralgia (PHN)","status":"COMPLETED","sponsor":"XenoPort, Inc.","startDate":"2008-02","conditions":"Neuralgia, Postherpetic","enrollment":376},{"nctId":"NCT00643760","phase":"PHASE2","title":"A Study In Patients With Neuropathic Pain From Diabetic Peripheral Neuropathy (DPN)","status":"COMPLETED","sponsor":"XenoPort, Inc.","startDate":"2008-03","conditions":"Neuropathy, Diabetic","enrollment":421},{"nctId":"NCT00748098","phase":"PHASE3","title":"Polysomnography Study of GSK1838262 Extended Release Tablets Versus Placebo in RLS and Associated Sleep Disturbance","status":"COMPLETED","sponsor":"XenoPort, Inc.","startDate":"2008-10","conditions":"Restless Legs Syndrome, Restless Legs Syndrome (RLS)","enrollment":136},{"nctId":"NCT00742209","phase":"PHASE2","title":"Prevention Study in Adult Patients Suffering From Migraine Headaches","status":"COMPLETED","sponsor":"XenoPort, Inc.","startDate":"2008-08","conditions":"Migraine Disorders, Migraine","enrollment":526},{"nctId":"NCT01411124","phase":"PHASE1","title":"Study to Assess the Effect of Gabapentin Enacarbil on Simulated Driving in Healthy Subjects","status":"COMPLETED","sponsor":"XenoPort, Inc.","startDate":"2011-06","conditions":"Restless Legs Syndrome (RLS)","enrollment":36},{"nctId":"NCT01476124","phase":"PHASE1","title":"Drug Drug Interaction Study With Gabapentin Enacarbil and Morphine","status":"COMPLETED","sponsor":"XenoPort, Inc.","startDate":"2011-08","conditions":"Restless Legs Syndrome","enrollment":18},{"nctId":"NCT00298623","phase":"PHASE3","title":"XP13512 (GSK1838262) Versus Placebo in Patients With Restless Legs Syndrome.","status":"COMPLETED","sponsor":"XenoPort, Inc.","startDate":"2006-03","conditions":"Restless Legs Syndrome","enrollment":222}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"XP13512 (GSK1838262)","genericName":"XP13512 (GSK1838262)","companyName":"XenoPort, Inc.","companyId":"xenoport-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"XP13512, also known as GSK1838262, is a small molecule that modulates voltage-gated calcium channels. It has been studied in clinical trials for conditions such as Restless Legs Syndrome, diabetic neuropathy, and postherpetic neuralgia.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}